Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human FMX-8 single and multiple ascending dose study in healthy male volunteers
NL-OMON37770Phase 1Active, not recruiting
- Sponsor
- FerruMax Pharmaceuticals, Inc.
- Start
- Feb 2012
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of FMX-8 in anaemia and iron deficiency anemia (IDA) (4 arms), sponsored by FerruMax Pharmaceuticals, Inc. Primary endpoints: Safety and tolerability of FMX-8 and Pharmacokinetics of FMX-8. Started Feb 2012; status: active, not recruiting.
02
Drugs
FMX-8
03
Conditions
anaemiairon deficiency anemia (IDA)
Beyond the preview
Go deeper on NL-OMON37770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37770.